TORL-1-23

TORL Biotherapeutics, LLC · Phase 2 active Small molecule

At a glance

Generic name	TORL-1-23
Sponsor	TORL Biotherapeutics, LLC
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

First in Human Study of TORL-1-23 in Participants With Advanced Cancer (PHASE1)
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer (PHASE1, PHASE2)
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TORL-1-23 CI brief — competitive landscape report
TORL-1-23 updates RSS · CI watch RSS
TORL Biotherapeutics, LLC portfolio CI